CEO SUMMARY: The urine drug testing industry is challenged every day to detect the large number of patients trying to cheat on their drug tests. GenoTox Laboratories of Austin, Texas, developed a DNA-authentication method for urine samples that allows the lab to detect when patients have used a substitute for urine when undergoing medication- and
Tag: disruptive technology
CEO SUMMARY: Clinical laboratories of all sizes are poised to become the source of much of a hospital or health system’s “big data.” At many academic center labs, greater use of genetic and molecular testing requires that more space and more staff be devoted to data management. At the same time, the latest generation of gene sequencing instruments and molecular analyzers are cheaper, faster, and more automated. These systems make it feasible for even smaller labs to offer sophisticated genetic tests.
In certain respects, the noted physician and healthcare strategist Eric Topol, M.D., of Scripps Healthcare in La Jolla, California, can be considered a gadfly to pathology and the laboratory medicine profession. In his latest pronouncements on patient-centered healthcare, he warned clinical labs about the need to stay ahead of the technology wave that is transforming
CEO SUMMARY: With each passing month, Theranos pulls open the curtain a bit more on its business structure and its market growth plans. Its clinical lab tests are now offered in Walgreens pharmacies in Palo Alto, California, and Phoenix, Arizona. Recent news coverage in Fortune and USAToday disclosed that company officials—based on stock sales to
WE ARE SWIFTLY APPROACHING THE DAY when community hospital-based pathologists will be able to serve hospitals and physicians located across state lines with the same ease that they serve hospitals and office-based physicians in their own cities and regions.
In the same vein, at least two major academic pathology groups in the United States have announced
CEO SUMMARY: In the same way that the Human Genome Project was disrupted by the entry of C. Craig Venter and Perkin-Elmer in what was then a 15-year, $3 billion project, now Complete Genetics of Mountain View, California, is disrupting the race to the $1,000 human genome sequence. Developments in this field are moving at
CEO SUMMARY: Forget CHINs from the 1990s and RHIOs from this decade. The future of regional health data repositories may turn out to be a patient-controlled model, often called a “Health Record Bank” (HRB). Here is the lab industry’s first look at this nascent movement. HRBs are under development in Louisville, Kentucky, the State of
CEO SUMMARY: This exclusive intelligence briefing predicts how specific new technologies may drive changes in the laboratory-testing marketplace during the next five years. The key message is that change is expected to be incremental, not disruptive—given the technology known to be in development at this time. But the more provocative insight relates to how even
CEO SUMMARY: As new diagnostic technologies move through the development pipeline and into widespread clinical use, the scientific knowledge and skill sets needed by laboratory staff and management will change. The emphasis in laboratory medicine will evolve to include more molecular technology, but this evolution will proceed incrementally, giving all laboratories time to adapt.
CEO SUMMARY: Clinical laboratories and pathology group practices are beginning to respond to a new set of marketplace trends. Speaker after speaker at this EXECUTIVE WAR COLLEGE included new business strategies not heard in past years. Probably the most notable difference is a growing emphasis on developing and delivering value-added services which go beyond simply